TGCT包括结节型和弥漫性两种类型,前者发展缓慢,后者可出现局部侵袭性行为。TGCT虽然通常不会危及生命,但可能引起慢性疼痛并影响日常生活和活动。 目前手术切除是TGCT的标准治疗方法,但并非所有患者都适合手术治疗。2022年发表于国际期刊《Cancer Treatment Reviews》的“腱鞘巨细胞瘤的最佳临床管理专家共识”[1]中指出,现有...
We found no increase in risk of cancer overall (Norway O/E=0.8; 95% CI: 0.6–1.1 and United States O/E=0.9; 95% CI: 0.7–1.3). Site-specific analyses pooled across the two countries revealed a leukemia excess (O/E=6.5; 95% CI: 3.0–12.3), deficit of female breast cancer (O/...
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care View More BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC View More Fighting Disparities and Saving Lives: An Explo...
[5] van, I. D. G. P. et al. Interactions in CSF1-Driven Tenosynovial Giant Cell Tumors. Clin Cancer Res 28, 4934-4946, doi:10.1158/1078-0432.CCR-22-1898 (2022). [6] Zhao, Y. et al. Gene Expression Profiles Analyzed Using Integrating RNA Sequenci...
Cancer cells with pink bubbles: © Adobe Contributor - stock.adobe.comNormal Pimicotinib (ABSK021) led to an objective response rate (ORR) at week 25 of 54.0% in patients with tenosynovial giant cell tumor (TGCT) vs 3.2% for placebo (P <.0001) based on RECIST v1.1 per Blinded Indep...
近年来,在国内外学术期刊上发表研究论文188余篇(其中,SCI论文77篇),以第一/通讯作者在Mol Cancer(1篇,IF: 41.4)、Nano Today(1篇,IF: 20.722)、Adv Funct Mater(3篇,IF: 19.9)、Advanced Science(1篇,IF: 17.5)、Bioactive Materials(1篇,IF: 16.8)、Biomaterials(3篇,IF: 15.3)等,已获国家专利授权57...
R. Lor Randall, MD, FACS, The David Linn Endowed Chair for Orthopedic Surgery, chair, Department of Orthopedic Surgery, professor, UC Davis Comprehensive Cancer Center, discusses findings from a study of one-stage synovectomy in patients with diffuse-type tenosynovial giant cell tumor (D-TGCT)...
The company has obtained approval from China NMPA to conduct Phase II clinical studies in chronic graft-versus-host disease (cGVHD) and advanced pancreatic cancer. PHASE III MANEUVER (ABSK021-301) STUDY The Phase III MANEUVER (ABSK021-301) study is a randomized, double-blind, placebo-...
(NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced positive top-line results from the MOTION pivotal Phase 3 study of vimseltinib in patients ...
Cancer Cell 7:263–273. https:// doi.org/10.1016/j.ccr.2005.02.010 17. Cookson MR (2010) DJ-1, PINK1, and their effects on mitochon- drial pathways. Mov Disord 25(Suppl 1):S44–S48. https://d oi.o rg/ 10.1002/mds....